Medicines in Breast Milk and Estimated Infant Exposure

NCT ID: NCT07346716

Last Updated: 2026-01-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-12-20

Study Completion Date

2030-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The MedMilk (Medication concentrations in human Milk) study investigates how selected medicines taken by breastfeeding women are transferred into human milk and whether this may affect the breastfed child. The study includes breastfeeding women who are already using prescription or over-the-counter medicines as part of their usual care. Participants provide samples of breast milk and urine and complete a questionnaire about maternal and infant health. The collected data will be used to quantify medicine concentrations in milk and estimate the relative infant dose. The study aims to contribute new data to support safer prescribing and more informed counselling during breastfeeding

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The MedMilk (Medication concentrations in human Milk) study is a prospective, exploratory clinical study coordinated by the Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, Denmark. The study is observational in nature and involves no experimental drug administration. Participants are breastfeeding women using medicines as part of their routine treatment.

Each participant will provide four small breast milk samples (1-20 mL each) collected at different time points in relation to maternal drug intake, one urine sample, and questionnaire data on maternal and infant health, breastfeeding patterns, and any infant symptoms potentially related to drug exposure. Samples are stored at -80 °C in a dedicated research biobank until analysis.

Drug concentrations in milk and urine will primarily be quantified using solid Phase Extraction coupled with UPLC-MS/MS. Data will be analyzed descriptively, and relative infant doses (RID) will be calculated. For drugs with sufficient sampling density.

Results will add to the limited body of systematic data on drug transfer into human milk and help inform clinical decision-making regarding medication use during breastfeeding.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breastfeeding Medication Safety Lactation Drug Exposure Via Breast Milk Pharmacokinetic Parameters

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Breastfeeding women on medication

Prescription Drugs

Intervention Type DRUG

Exposure to prescription medicines taken by breastfeeding women during routine treatment. The study does not assign medications but observes drug transfer into human milk from exposures occurring as part of usual care.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Prescription Drugs

Exposure to prescription medicines taken by breastfeeding women during routine treatment. The study does not assign medications but observes drug transfer into human milk from exposures occurring as part of usual care.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Lactating women aged ≥18 years
* Current use of one or more prescription or over-the-counter (classified within the ATC system) drugs
* Able and willing to provide written informed consent

Exclusion Criteria

* Current pregnancy during sample collection
* Known and clinically significant pharmacokinetic drug-drug interactions at the time of sampling
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital Bispebjerg and Frederiksberg

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jón Þór Trærup Andersen

Professor, PhD,

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jon Traerup Andersen, Professor, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Department of Clinical Pharmacology, Bispbjeg and Frederiksberg Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Clinical Pharmacology

Copenhagen, , Denmark

Site Status RECRUITING

Mental health services, Capital Region of Denmark

Copenhagen, , Denmark

Site Status RECRUITING

Department of Obstetrics and Gynecology, Herlev Hospital

Herlev, , Denmark

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ditte Resendal Gotfredsen, MD

Role: CONTACT

+4521472051

Jon Traerup Andersen, Professor, MD, PhD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ditte Resendal Gotfredsen, MD

Role: primary

+4521472051

Jon Traerup Andersen, Professor, MD, PhD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

H-23062687

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Drug Excretion in Breast Milk
NCT06056583 RECRUITING PHASE4
Metformin to Augment Low Milk Supply (MALMS) Study
NCT02179788 COMPLETED PHASE1/PHASE2